AccScience Publishing / GTM / Volume 2 / Issue 2 / DOI: 10.36922/gtm.0389
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Novel applications of manipulating gut microbiota for alleviating hematological disorders

Sibusiso Luthuli1* Lulama Luthuli2
Show Less
1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People’s Hospital, Nanjing, 210029, China
2 Department of Paediatric Surgery, Kalafong Academic Hospital of the University of Pretoria, Pretoria, 0001, South Africa
Global Translational Medicine 2023, 2(2), 0389
Submitted: 3 April 2023 | Accepted: 16 June 2023 | Published: 30 June 2023
© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

Investigations toward malignancies involving gut microbiota are still in their infancy, especially in hematology and oncology. There are approximately 1.2 million new hematological malignancy cases, resulting in more than 500,000 cases/year in mortality worldwide. It is through commendable advancements directed toward anticancer therapy in recent times that have significantly improved the survival rate among individuals; however, their cytotoxicity or side effects tend to be challenging for patients to tolerate, attributed to anticancer therapies such as chemotherapy and/or radiation therapy due to the aggressive nature in terms of their mechanism of action. Therefore, novel means, or treatments that could present less or non-toxic modalities are warranted, especially those that decrease unpleasant side effects. Studies indicate that the human body accommodates roughly 40 trillion microorganisms, also referred to as the human microbiota, and the abundance of this microbiota is predominantly found in the gastrointestinal tract. The microbiota is associated with various physiological roles, like immunology, digestive functions, and neural development. Therefore, the aim of this literature is to summarize current innovations (and achievements) in using gut microbiota to alleviate diseases and possible directions to explore toward curing malignancies or associated ailments. In addition, this type of publication seeks to encourage possible directions to be employed in establishing “possible biomarkers” which could be used in both the laboratory and clinical settings; this includes methodologies involving translational medicine through undertakings of improving cancer therapy.

Hematological malignancies
  1. Watson HR, Burr SA, 2022, Botulinum toxin. In: Reference Module in Biomedical Sciences. Amsterdam: Elsevier.


  1. Corrigan M, Roberts K, Steiger E, editors., 2018, Adult Short Bowel Syndrome: Nutritional, Medical, and Surgical Management. San Diego, CA: Academic Press.


  1. Levy M, Kolodziejczyk AA, Thaiss CA, et al., 2017, Dysbiosis and the immune system. Nat Rev Immunol, 17: 219–232.


  1. Hakansson A, Molin G, 2011, Gut microbiota and inflammation. Nutrients, 3: 637–682.


  1. Sonnenburg ED, Sonnenburg JL, 2014, Starving our microbial self: The deleterious consequences of a diet deficient in microbiota-accessible carbohydrates. Cell Metab, 20: 779–786.


  1. De Palma G, Lynch MD, Lu J, et al., 2017, Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med, 9: eaaf6397.


  1. Beaumont M, Goodrich JK, Jackson MA, et al., 2016, Heritable components of the human fecal microbiome are associated with visceral fat. Genome Biol, 17: 189.


  1. Wiley NC, Dinan TG, Ross RP, et al., 2017, The microbiota-gut-brain axis as a key regulator of neural function and the stress response: Implications for human and animal health. J Anim Sci, 95: 3225–3246.


  1. Falony G, Joossens M, Vieira-Silva S, et al., 2016, Population-level analysis of gut microbiome variation. Science, 352: 560–564.


  1. Wong JM, de Souza R, Kendall CW, et al., 2006, Colonic health: Fermentation and short chain fatty acids. J Clin Gastroenterol, 40: 235–243.


  1. Byndloss MX, Olsan EE, Rivera-Chávez F, et al., 2017, Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science, 357: 570–575.


  1. De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al., 2014, Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell, 156: 84–96.


  1. Frost G, Sleeth ML, Sahuri-Arisoylu M, et al., 2014, The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun, 5: 3611.


  1. Manichanh C, Rigottier-Gois L, Bonnaud E, et al., 2006, Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut, 55: 205–211.


  1. De Goffau MC, Luopajärvi K, Knip M, et al., 2013, Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes, 62: 1238–1244.


  1. Lambeth SM, Carson T, Lowe J, et al., 2015, Composition, diversity and abundance of gut microbiome in prediabetes and Type 2 diabetes. J Diabetes Obes, 2: 1–7.


  1. Schippa S, Iebba V, Barbato M, et al., 2010, A distinctive “microbial signature” in celiac pediatric patients. BMC Microbiol, 10: 175.


  1. Menni C, Lin C, Cecelja M, et al., 2018, Gut microbial diversity is associated with lower arterial stiffness in women. Eur Heart J, 39: 2390–2397.


  1. Scher JU, Ubeda C, Artacho A, et al., 2015, Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol, 67: 128–139.


  1. Turnbaugh PJ, Hamady M, Yatsunenko T, et al., 2009, A core gut microbiome in obese and lean twins. Nature, 457: 480–484.


  1. Opstelten JL, Plassais J, van Mil SW, et al., 2016, Gut microbial diversity is reduced in smokers with Crohn’s disease. Inflamm Bowel Dis, 22: 2070–2077.


  1. Sommer F, Anderson JM, Bharti R, et al., 2017, The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol, 15: 630–638.


  1. Sommer F, Rühlemann MC, Bang C, et al., 2017, Microbiomarkers in inflammatory bowel diseases: Caveats come with caviar. Gut, 66: 1734–1738.


  1. Tomblyn M, Chiller T, Einsele H, et al., 2009, Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant, 15: 1143–1238.


  1. Van Vliet MJ, Harmsen HJM, de Bont ESJ, et al., 2010, The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog, 6: e1000879.


  1. Sonis ST, 2004, The pathobiology of mucositis. Nat Rev Cancer, 4: 277–284.


  1. Young VB, 2017, The role of the microbiome in human health and disease: An introduction for clinicians. BMJ, 356: j831.


  1. Taur Y, Xavier JB, Lipuma L, et al., 2012, Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis, 55: 905–914.


  1. Rauff B, Idrees M, Shah SAR, et al., 2011, Hepatitis associated aplastic anemia: A review. Virol J, 8: 87.


  1. Peyssonnaux C, Zinkernagel AS, Datta V, et al., 2006, TLR4- dependent hepcidin expression by myeloid cells in response to bacterial pathogens. Blood, 107: 3727–3732.


  1. Zimmerman MA, Singh N, Martin PM, et al., 2012, Butyrate suppresses colonic inflammation through HDAC1- dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol, 302: G1405–G1415.


  1. Cines DB, Liebman H, Stasi R, 2009, Pathobiology of secondary immune thrombocytopenia. Semin Hematol, 46: S2–S14.


  1. Pockros PJ, Duchini A, McMillan R, et al., 2002, Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol, 97: 2040–2045.


  1. Kaser A, Brandacher G, Steurer W, et al., 2001, Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood, 98: 2720–2725.


  1. Jenq RR, Taur Y, Devlin SM, et al., 2015, Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant, 21: 1373–1383.


  1. Jacobsohn DA, Vogelsang GB, 2007, Acute graft versus host disease. Orphanet J Rare Dis, 2: 35.


  1. Heimesaat MM, Nogai A, Bereswill S, et al., 2010, MyD88/ TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut, 59: 1079–1087.


  1. Van Vliet MJ, Tissing WJE, Dun CAJ, et al., 2009, Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis, 49: 262–270.


  1. Guo H, Chou WC, Lai Y, et al., 2020, Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science, 370: eaay9097.


  1. Weber D, Oefner PJ, Hiergeist A, et al., 2015, Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood, 126: 1723–1728.


  1. Jenq RR, Ubeda C, Taur Y, et al., 2012, Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med, 209: 903–911.


  1. Dubin K, Callahan MK, Ren B, et al., 2016, Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun, 7: 10391.


  1. Chaput N, Lepage P, Coutzac C, et al., 2017, Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol, 28: 1368–1379.


  1. Shen S, Lim G, You Z, et al., 2017, Gut microbiota is critical for the induction of chemotherapy-induced pain. Nat Neurosci, 20: 1213–1216.


  1. Wang Y, Wiesnoski DH, Helmink BA, et al., 2018, Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med, 24: 1804–1808.


  1. Huang Y, Yang W, Liu H, et al., 2012, Effect of high-dose methotrexate chemotherapy on intestinal Bifidobacteria, Lactobacillus and Escherichia coli in children with acute lymphoblastic leukemia. Exp Biol Med (Maywood), 237: 305–311.


  1. Montassier E, Gastinne T, Vangay P, et al., 2015, Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther, 42: 515–528.


  1. Scully C, Epstein J, Sonis S, 2003, Oral mucositis: A challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: Part 1, pathogenesis and prophylaxis of mucositis. Head Neck, 25: 1057–1070.


  1. Iida N, Dzutsev A, Stewart CA, et al., 2013, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science, 342: 967–970.


  1. Matutes E, 2007, Adult T-cell leukaemia/lymphoma. J Clin Pathol, 60: 1373–1377.


  1. Hanahan D, Weinberg RA, 2000, The hallmarks of cancer. Cell, 100: 57–70.


  1. Newman JV, Kosaka T, Sheppard BJ, et al., 2001, Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. J Infect Dis, 184: 227–230.


  1. Wu S, Rhee KJ, Albesiano E, et al., 2009, A human colonic commensal promotes colon tumorigenesis via activation of T helper Type 17 T cell responses. Nat Med, 15: 1016–1022.


  1. Diwan BA, Ward JM, Ramljak D, et al., 1997, Promotion by Helicobacter hepaticus-induced hepatitis of hepatic tumors initiated by N-nitrosodimethylamine in male A/JCr mice. Toxicol Pathol, 25: 597–605.


  1. Yamamoto ML, Maier I, Dang AT, et al., 2013, Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res, 73: 4222–4232.


  1. Barlow C, Hirotsune S, Paylor R, et al., 1996, Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell, 86: 159–171.


  1. Reliene R, Schiestl RH, 2006, Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst), 5: 852–859.


  1. Reliene R, Schiestl RH, 2006, Differences in animal housing facilities and diet may affect study outcomes-a plea for inclusion of such information in publications. DNA Repair (Amst), 5: 651–653.


  1. Fujiwara D, Wei B, Presley LL, et al., 2008, Systemic control of plasmacytoid dendritic cells by CD8+ T cells and commensal microbiota. J Immunol, 180: 5843–5852.


  1. West NR, Powrie F, 2015, Immunotherapy not working? Check your microbiota. Cancer Cell, 28: 687–689.


  1. Arpaia N, 2013, Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature, 504: 451–455.


  1. Vetizou M, Pitt JM, Daillere R, et al., 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350: 1079–1084.


  1. Sivan A, Corrales L, Hubert N, et al., 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 350: 1084–1089.


  1. Pitt JM, Vetizou M, Boneca IG, et al., 2017, Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. Oncoimmunology, 6: e1132137.


  1. Routy B, Le Chatelier E, Derosa L, et al., 2018, Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 359: 91–97.


  1. Gopalakrishnan V, Spencer CN, Nezi L, et al., 2018, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 359: 97–103.


  1. Du C, Luo Y, Walsh S, et al., 2021, Oral fecal microbiota transplant capsules are safe and effective for recurrent Clostridioides difficile infection: A systematic review and meta-analysis. J Clin Gastroenterol, 55: 300–308.


  1. Umesaki Y, Setoyama H, Matsumoto S, et al., 1993, Expansion of alpha beta T-cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. Immunology, 79: 32–37.


  1. McDonald LC, Gerding DN, Johnson S, et al., 2018, Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA). Clin Infect Dis, 66: e1–e48.


  1. Kim S, Covington A, Pamer EG, 2017, The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens. Immunol Rev, 279: 90–105.


  1. Innes AJ, Mullish BH, Fernando F, et al., 2017, Faecal microbiota transplant: A novel biological approach to extensively drug-resistant organism-related non-relapse mortality. Bone Marrow Transplant, 52: 1452–1454.


  1. Biliński J, Grzesiowski P, Muszyński J, et al., 2016, Fecal microbiota transplantation inhibits multidrug-resistant gut pathogens: Preliminary report performed in an immunocompromised host. Arch Immunol Ther Exp (Warsz), 64: 255–258.


  1. De Castro CG Jr., Ganc AJ, Ganc RL, et al., 2015, Fecal microbiota transplant after hematopoietic SCT: Report of a successful case. Bone Marrow Transplant, 50: 145.


  1. Kaito S, Toya T, Yoshifuji K, et al., 2018, Fecal microbiota transplantation with frozen capsules for a patient with refractory acute gut graft-versus-host disease. Blood Adv, 2: 3097–3101.


  1. Rajagopala SV, Yooseph S, Harkins DM, et al., 2016, Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis. BMC Genomics, 17: 635.


  1. Han L, Zhang H, Chen S, et al., 2019, Intestinal microbiota can predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 25: 1944–1955.


  1. Galloway-Peña JR, Smith DP, Sahasrabhojane P, et al., 2016, The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 122: 2186–2196.


  1. Pepeljugoski CA, Morgan G, Braunstein M, 2019, Analysis of intestinal microbiome in multiple myeloma reveals progressive dysbiosis compared with MGUS and healthy individuals. Blood, 134: 3076.


  1. Pianko MJ, Devlin SM, Littmann ER, et al., 2019, Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Adv, 3: 2040–2044.


  1. Peled JU, Devlin SM, Staffas A, et al., 2017, Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol, 35: 1650–1659.


  1. Reichardt N, Duncan SH, Young P, et al., 2014, Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. ISME J, 8: 1323–1335.


  1. Smith PM, 2013, The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science, 341: 569–573.


  1. Luthuli S, Wu S, Cheng Y, et al., 2019, Therapeutic effects of fucoidan: A review on recent studies. Mar Drugs, 17: 487.


  1. Mirzaei R, Afaghi A, Babakhani S, et al., 2021, Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother, 139: 111619.


  1. Zeng H, Lazarova DL, Bordonaro M, 2014, Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. World J Gastrointest Oncol, 6: 41–51.


  1. Song M, Garrett WS, Chan AT, 2015, Nutrients, foods, and colorectal cancer prevention. Gastroenterology, 148: 1244–1260.e16.


  1. Dahiya D, Nigam PS, 2022, The gut microbiota influenced by the intake of probiotics and functional foods with prebiotics can sustain wellness and alleviate certain ailments like gut-inflammation and colon-cancer. Microorganisms, 10: 665.


  1. Aponte M, Murru N, Shoukat M, 2020, Therapeutic, prophylactic, and functional use of probiotics: A current perspective. Front Microbiol, 11: 562048.


  1. Zagato E, Pozzi C, Bertocchi A, et al., 2020, Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol, 5: 511–524.


  1. Lu Y, Yuan X, Wang M, et al., 2022, Gut microbiota influence immunotherapy responses: Mechanisms and therapeutic strategies. J Hematol Oncol, 15: 47.


  1. Parida S, Sharma D, 2021, The microbiome and cancer: Creating friendly neighborhoods and removing the foes within. Cancer Res, 81: 790–800.


  1. Gupta VK, Paul S, Dutta C, 2017, Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol, 8: 1162.


  1. Rudi K, Zhao L, 2021, Grand challenges in understanding gut microbes. Front Microbiol, 12: 752829.


  1. Campbell JH, Foster CM, Vishnivetskaya T, et al., 2012, Host genetic and environmental effects on mouse intestinal microbiota. ISME J, 6: 2033–2044.


  1. Hildebrand F, Nguyen TLA, Brinkman B, et al., 2013, Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol, 14: R4.


  1. Jobin C, 2018, Precision medicine using microbiota. Science, 359: 32–34.


  1. Zmora N, Soffer E, Elinav E, 2019, Transforming medicine with the microbiome. Sci Transl Med, 11: eaaw1815.


  1. Gupta A, Khanna S, 2017, Fecal microbiota transplantation. JAMA, 318: 102.


  1. Wang JW, Kuo CH, Kuo FC, et al., 2019, Fecal microbiota transplantation: Review and update. J Formos Med Assoc, 118: S23–S31.


  1. Hadrich D, 2018, Microbiome research is becoming the key to better understanding health and nutrition. Front Genet, 9: 212.


  1. Berg G, 2009, Plant-microbe interactions promoting plant growth and health: Perspectives for controlled use of microorganisms in agriculture. Appl Microbiol Biotechnol, 84: 11–18.


  1. Mirzayi C, Renson A, Furlanello C, et al., 2021, Reporting guidelines for human microbiome research: The STORMS checklist. Nat Med, 27: 1885–1892.


  1. Sinha R, Abnet CC, White O, et al., 2015, The microbiome quality control project: Baseline study design and future directions. Genome Biol, 16: 276.


  1. Sinha R, Abu-Ali G, Vogtmann E, et al., 2017, Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium. Nat Biotechnol, 35: 1077–1086.


  1. Poussin C, Sierro N, Boué S, et al., 2018, Interrogating the microbiome: Experimental and computational considerations in support of study reproducibility. Drug Discov Today, 23: 1644–1657.
Conflict of interest
The author declares no conflicts of interest.
Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Published by AccScience Publishing